RECHF News Today: Stay Updated with the Latest Recharge Resources Ltd. News in Real Time
Find RECHF news now at Meyka AI. Stay informed with the latest{" "} Recharge Resources Ltd. stocks updates, including price news, market analysis, and expert insights.
Ethereum RSI Hits Record Low as ETH Drops to $1,702, June 08
Ethereum drops 4% to $1,702 as monthly RSI hits record low of 40. Meyka rates ETH a C+ with $2,894 yearly target. Whales accumulate amid ETF outflows.
MDAX Falls 0.71% on Rate Hike Fears and Tech Weakness, June 08
MDAX drops 0.71% to 32,235 points on June 08 as rate hike fears and tech weakness pressure German mid-cap stocks.
STI Falls 1.7% to 4,963.67 on Tech Rout and Middle East Tensions, June 08
Singapore’s STI index fell 1.7% to 4,963.67 on June 8 amid global tech selloff and Middle East tensions. Semiconductors led losses.
Uchida Faces 27-Year Sentence in Asahikawa Teen Murder Case, June 08
Prosecutors seek 27-year sentence for Riko Uchida in Asahikawa bridge death case. Victim’s father appeals for justice as defense denies murder intent.
BP Shares Fall 12% to £5.46 as Oil Peace Deal Weighs, June 08
BP shares fall 12% to £5.46 on Iran peace deal expectations. JPMorgan holds 600p target; analyst consensus at 635p. CEO change supports oil focus.
Murata Stock Drops 12% on Tech Selloff, June 08
Murata Manufacturing stock fell 12% to ¥8,711 on June 08 amid AI concerns and Middle East tensions. Meyka rates it B.
Hong Kong Markets Face Fraud Alerts as Banks Issue Warnings, June 08
Hong Kong banks issue fraud alerts as HKMA warns of phishing sites targeting Alipay and bank customers. Protect your account credentials.
UKSSSC Opens 90 Agriculture Officer Posts, Fake Letters Spark Exam Fraud Fears
UKSSSC opens 90 Assistant Agriculture Officer vacancies with June 21 deadline amid fraud concerns over fake exam letters.
Eli Lilly Stock (LLY) Jumps 4% to $1,131.42 USD as Retatrutide Cuts Sleep Apnea by 60% in Phase 3 Trial
Eli Lilly stock gained approximately 4 percent and climbed to $1,131.42 USD after the company announced promising Phase 3 clinical trial results for Retatrutide. The experimental drug demonstrated a remarkable ability to reduce obstructive sleep apnea severity by nearly 60 percent, generating excitement among investors and healthcare professionals. The announcement strengthened confidence in Eli Lilly’s…